Stockreport

OPKO Health’s ModeX Therapeutics Begins Clinical Trial of Tetraspecific Antibody for Treatment of B-cell Lymphomas

Opko Health, Inc.  (OPK) 
Last opko health, inc. earnings: 2/26 04:05 pm Check Earnings Report
US:NYSE Investor Relations: investor.opko.com
PDF Patients dosed in Phase 1 safety and tolerability study of MDX2003, a novel T-cell engager designed to optimize killing of lymphomas Preclinical studies presented at 20 [Read more]